SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab plus talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC)

被引：0
|
作者：
Abdel Karim, Nagla Fawzy
Miao, Jieling
Reckamp, Karen L.
Michael Gay, Carl
Averett Byers, Lauren
Zhao, Yingqi
Weber Redman, Mary
Carrizosa, Daniel R.
Wang, Wei-Lien
Petty, William J.
Mehta, Kathan
Faller, Bryan A.
Agamah, Edem S.
Kasbari, Samer S.
Katipamula Malisetti, Rajini
Kumar, Atul
Schallenkamp, John
Chaitanya Alluri, Krishna
Elaine Gray, Jhanelle
Kelly, Karen
机构：
[1] Univ Virginia, Inova Schar Canc Inst, Fairfax, VA USA
[2] SWOG Stat Ctr, Fred Hutchinson Canc Res Ctr, Seattle, WA USA
[3] Cedars Sinai Med Ctr, Los Angeles, CA USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[6] SWOG Stat & Data Management Ctr, Fred Hutchinson Canc Ctr, Seattle, WA USA
[7] Levine Canc Inst, Charlotte, NC USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX USA
[9] Wake Forest Coll, Winston Salem, NC USA
[10] Missouri Baptist Med Ctr, St Loius, MO USA
[11] Southern Illinois Univ, Springfield, IL USA
[12] Southeastern Med Oncol Ctr, Goldsboro, NC USA
[13] Minnesota Oncol Hematol, Coon Rapids, MN USA
[14] Univ New Mexico Comprehens Canc Ctr, Albuquerque, NM USA
[15] Billings Clin, Billings, MT USA
[16] St Lukes Canc Inst, Boise, ID USA
[17] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[18] UC Davis Comprehens Canc Ctr, Sacramento, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8504
引用
收藏
页数：1
相关论文
共 50 条
  • [41] SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) plus carboplatin plus etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC).
    Rudin, Charles M.
    Liu, Stephen V.
    Lu, Shun
    Soo, Ross A.
    Hong, Min Hee
    Lee, Jong-Seok
    Bryl, Maciej
    Dumoulin, Daphne W.
    Rittmeyer, Achim
    Chiu, Chao-Hua
    Ozyilkan, Ozgur
    Navarro, Alejandro
    Novello, Silvia
    Ozawa, Yuichi
    Meng, Raymond
    Hoang, Tien
    Lee, Anthony
    Wen, Xiaohui
    Huang, Meilin
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [42] Phase II, multicenter, randomized, open-label study of DS-7300 in patients (pts) with pre-treated extensive-stage small cell lung cancer (ES-SCLC)
    Paz-Ares, L.
    Johnson, M. L.
    Girard, N.
    Hann, C. L.
    Ahn, M-J.
    Nishio, M.
    Godard, J.
    Laadem, A.
    Yoshizuka, N.
    Qian, M.
    Cheng, B.
    Rudin, C. M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1255 - S1256
  • [43] A NEW PROGNOSTIC MODEL FOR RELAPSED/REFRACTORY EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC) DERIVED FROM PROSPECTIVE SWOG TRIALS: IMPLICATIONS FOR STUDY DESIGN
    Lara, Primo
    Moon, James
    Redman, Mary
    Kelly, Karen
    Allen, Jeffrey
    Gitlitz, Barbara
    Mack, Philip
    Gandara, David
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S222 - S222
  • [44] A phase II trial of carboplatin and irinotecan as first-line therapy for extensive stage small cell lung cancer (ES-SCLC): Preliminary results
    Laskin, J
    Shirley, B
    Dobbs, T
    Bi, J
    Carbone, D
    Johnson, D
    Sandler, A
    LUNG CANCER, 2005, 49 : S323 - S323
  • [45] Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study
    Tiandong Kong
    Lu Chen
    Xiaoli Zhao
    Fangfang Duan
    Hanli Zhou
    Lei Wang
    Danna Liu
    Investigational New Drugs, 2022, 40 : 1095 - 1105
  • [46] Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study
    Kong, Tiandong
    Chen, Lu
    Zhao, Xiaoli
    Duan, Fangfang
    Zhou, Hanli
    Wang, Lei
    Liu, Danna
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 1095 - 1105
  • [47] Phase II study of anlotinib plus durvalumab and chemotherapy as first-line treatment in extensive-stage small cell lung cancer (ES-SCLC): Efficacy and safety analysis.
    Chen, Lijuan
    Zhao, Yanqiu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] International Multicenter Randomized Study on Thoracic Radiation Therapy (RT) in Extensive Stage Small Cell Lung Cancer (ES-SCLC): Patterns of Disease Recurrence
    Slotman, B. J.
    Faivre-Finn, C.
    van Tinteren, H.
    Praag, J.
    Knegjens, J.
    el Sharouni, S.
    Hatton, M.
    Keijser, A.
    Senan, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S3 - S4
  • [49] Imfirst: A phase IIIb, safety, single arm study of carboplatin (CB) or cisplatin (CP) plus etoposide (ET) with atezolizumab (ATZ) in patients with untreated extensive-stage small cell lung cancer (ES-SCLC) in Spain-Primary safety results of the induction phase.
    Garcia Campelo, Maria Rosario
    Domine, Manuel
    De Castro, Javier
    Moreno, Alberto
    Ponce Aix, Santiago
    Arriola, Edurne
    Carcereny, Enric
    Majem, Margarita
    Huidobro Vence, Gerardo
    Esteban, Emilio
    Fuentes Pradera, Jose
    Massuti, Bartomeu
    Laura Ortega, Ana
    Monica, Guillot
    Felipe Cordoba, Juan
    Fernandez, Natalia
    Alonso, Ruben
    Crama, Leonardo
    Lerones, Natalia
    Cobo, Manuel
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [50] A phase I study evaluating rovalpituzumab tesirine (ROVA-T) in frontline treatment of patients (pts) with extensive stage small cell lung cancer (ES-SCLC)
    Hann, C.
    Burns, T.
    Dowlati, A.
    Morgensztern, D.
    Koch, M.
    Chang, Y-W.
    Komarnitsky, P.
    Ludwig, C.
    Nimeiri, H.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2019, 30 : 711 - 712
12345